These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29439591)

  • 1. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
    Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
    Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH; Oh C; Hong S; Park W
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
    BioDrugs; 2020 Feb; 34(1):89-98. PubMed ID: 31734899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.
    Scherlinger M; Germain V; Labadie C; Barnetche T; Truchetet ME; Bannwarth B; Mehsen-Cetre N; Richez C; Schaeverbeke T;
    Joint Bone Spine; 2018 Oct; 85(5):561-567. PubMed ID: 29154920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
    Mahakkanukrauh A; Chaiamnuay S; Koolvisoot A; Kitamnuayphong T; Manavathongchai S; Osiri M; Louthrenoo W; Uea-Areewongsa P; Ahn K; Jung N; Kim M; Lee S; Kim H; Kim S
    Immunotherapy; 2023 Oct; 15(14):1143-1155. PubMed ID: 37589164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
    Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea.
    Kim DW; Lee Y; Kim G; Kim SH; Cho DH; Choi J; Kwon YH; Park Y; Choi W; Park DI
    Adv Ther; 2023 Mar; 40(3):1047-1061. PubMed ID: 36624354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
    Park W; Yoo DH; Miranda P; Brzosko M; Wiland P; Gutierrez-Ureña S; Mikazane H; Lee YA; Smiyan S; Lim MJ; Kadinov V; Abud-Mendoza C; Kim H; Lee SJ; Bae Y; Kim S; Braun J
    Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
    Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
    Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
    Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
    Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
    Clin Exp Rheumatol; 2020; 38(2):267-274. PubMed ID: 31365335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Shin K
    BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
    Westhovens R; Wiland P; Zawadzki M; Ivanova D; Kasay AB; El-Khouri EC; Balázs É; Shevchuk S; Eliseeva L; Stanislavchuk M; Yatsyshyn R; Hrycaj P; Jaworski J; Zhdan V; Trefler J; Shesternya P; Lee SJ; Kim SH; Suh JH; Lee SG; Han NR; Yoo DH
    Rheumatology (Oxford); 2021 May; 60(5):2277-2287. PubMed ID: 33230526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.